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Abstract
Background: In Lithuania, the vaccination coverage against pertussis is high. Nevertheless, there
is a significant increase in pertussis cases in fully immunized children. The aim of our study was to
determine the frequency of classical symptoms of laboratory confirmed pertussis and describe its
epidemiology in children fully vaccinated against pertussis.
Methods: From May to December 2001, 70 children aged 1 month to 15 years, suffering from
prolonged cough were investigated in the Centre of Paediatrics, Vilnius University Children's
Hospital. The collected information included personal data, vaccination history, clinical symptoms
of the current illness, and treatment before hospitalization. At the admission to the hospital blood
samples were taken from all studied children for Bordetella pertussis IgM and IgA.
Results:  A total of 53 (75.7%) of the 70 recruited patients with prolonged cough showed
laboratory evidence of pertussis. 32 of them were fully vaccinated with whole cell pertussis vaccine
(DTP). The age of fully vaccinated patients varied from 4 to 15 years (average 10.9 ± 3.1; median
11). The time period between the last vaccination dose (fourth) and the clinical manifestation of
pertussis was 2.6–13 years (average 8.9 ± 3.0; median 9). More than half of the children before the
beginning of pertussis were in contact with persons suffering from long lasting cough illness in the
family, school or day-care center. The mean duration from onset of pertussis symptoms until
hospitalization was 61.4 ± 68.3 days (range, 7 to 270 days; median 30). For 11 patients who had had
two episodes (waves) of coughing, the median duration of cough was 90 days, and for 21 with one
episode 30 days (p < 0.0002). Most of the children (84.4%) had paroxysmal cough, 31.3% had post-
tussive vomiting, 28.1% typical whoop, and 3.1% apnea. Only 15.6% children had atypical symptoms
of pertussis.
Conclusion: Fully vaccinated children fell ill with pertussis at the median of 11 years old, 9 years
following pertussis vaccination. More than half of the children could catch pertussis at home, at
school or day-care center. Clinical picture of pertussis in previously immunized children is usually
characterized by such classical symptoms as prolonged and paroxysmal cough, rarely by whopping
and post-tussive vomiting, and very rarely by apnea.
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Background
Pertussis is a highly communicable, vaccine-preventable
respiratory disease. The incidence of pertussis has been
greatly reduced by massive vaccination. Nevertheless,
there is a significant increase in pertussis cases in older
children, adolescents and adult people [1-4]. Improved
diagnosis, awareness of pertussis, genetic Bordetella pertus-
sis changes and waning of vaccine-induced immunity are
the possible reasons for increased incidence of pertussis
[1-5]. In the USA the incidence of vaccine-preventable dis-
eases such as measles, rubella, mumps, diphtheria, teta-
nus has been greatly reduced in the last 15 years.
However, the incidence of pertussis cases increased more
than twice: 8296 reported cases in 2002 versus 3450 in
1988 [6]. The age distribution of patients with pertussis in
the USA in 1994–1996 and 1997–2000 has changed. Dur-
ing the last period, the incidence of pertussis among
infants increased by 11%, in children aged 1–4 years
decreased to 8%, remained stable for children aged 5–9
years and among adolescents and adults increased by
about 60% [7].
In Lithuania immunization of infants and children
against pertussis has been introduced since 1956 and mas-
sive vaccination started in 1961. According to our stand-
ard vaccination schedule, pertussis whole-cell vaccine
incorporated in diphtheria-tetanus-pertussis (DTP) vac-
cine is offered at 3, 4.5 and 6 months of age with a booster
dose only at 18 months of age. In 1991, the vaccine cov-
erage among children aged 1 year was 73.2%, whereas this
percentage has been increasing and since 1996 reached
above 90% (93.6% in 2000, 94.6% in 2001). 35% of all
pertussis cases were diagnosed in vaccinated children (at
least three DTP vaccine doses) during the period from
1991 to 1995, 33.4% of the cases from 1996 to 2000 and
43.2% in 2001.
Clinical presentation of pertussis in unvaccinated chil-
dren had been extensively described by several authors
[8,9]. The disease in these patients is usually typical and
often severe. Data of the clinical course of pertussis in
fully immunized children is usually atypical and generally
mild [10].
The aim of our study was to determine the frequency of
classical symptoms of laboratory confirmed pertussis and
describe its epidemiology in fully vaccinated children.
Methods
From May to December 2001, 70 children aged 1 month
to 15 years with prolonged cough (duration ≥  14 days)
and siblings with shorter duration cough (but not less
than 7 days) were hospitalized and investigated at Vilnius
University Children's Hospital, Centre of Paediatrics. The
patients were referred to the hospital by general practi-
tioners or pediatricians, because detailed investigation of
the children with prolonged cough of unknown etiology
was only available in the hospital. The data regarding to
the patient's age, vaccination history, clinical symptoms
and signs of the current illness, previous treatment was
collected on to computer database. Single blood samples
were taken from all the children upon admission and sent
for detection of specific immunoglobulin (Ig) IgM and
IgA antibodies to B. pertussis by an enzyme-linked immu-
nosorbent assay (ELISA). Serological tests were performed
and estimated according to the manufacturer's instruc-
tions (Labsystems, Finland). Specimens for B. pertussis
and B. parapertussis culture were not obtained because of
the late illness stage and received previous antimicrobial
therapy before hospitalization. Classical symptoms of
pertussis were defined as a prolonged cough lasting two
weeks or more, paroxysmal cough, inspiratory whoop,
post-tussive vomiting and apnea. Confirmed case of per-
tussis was defined as an episode of cough lasting 7 days or
more and positive anti-B. pertussis IgM or IgA or both lev-
els. Two groups of our studied patients were compared.
One group of children with prolonged cough who had
two episodes (waves) of successive coughing (when first
episode was not ended, it means that cough become more
intensified and coughing paroxysm renewed) was com-
pared to the second group who had only one episode of
prolonged cough.
The descriptive values were expressed as means, medians
and standard deviations (SD) or percentages. Two-sided
Wilcoxon test for independent samples was used to com-
pare the groups. A p value less than 0.05 were considered
statistically significant.
Results
Of the 70 studied children, 53 (75.7%) showed a serolog-
ical evidence of pertussis. Out of 53 patients, 21 (39.6%)
were partially vaccinated or unvaccinated at all and 32
(60.4%) received complete vaccination. Out of 32 fully
vaccinated patients, positive B. pertussis IgM antibodies
were found in 6, IgA in 3 and both IgM and IgA in 23
patients.
We present epidemiological and clinical analysis of 32
children with confirmed pertussis who received 4 doses
whole-cell of pertussis vaccine. Only eight (25%) of 32
fully vaccinated children were referred to the hospital with
suspicion of pertussis, other referral diagnosis were bron-
chitis for 15 children, tracheobronchitis – 4, bronchop-
neumonia – 4, asthma exacerbation – 1. The
characteristics of the children with pertussis are listed in
Table 1. There was a difference in gender distribution:
male 34.4% and female 65.6%. The age of the patients
was from 4 to 15 years (average 10.9 ± 3.1; median 11).
Most of the children (75.0%) were older than 9 years. TheBMC Infectious Diseases 2005, 5:40 http://www.biomedcentral.com/1471-2334/5/40
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time period between the last (fourth) vaccination dose
and the clinical manifestation of pertussis was 2.6–13
years (average 8.9 ± 3.0; median 9). None of the children
had a history of pertussis. Seventeen (53.1%) children
before they got ill had been in contact with person suffer-
ing from long-lasting cough, 12 of them at home (all of
them with siblings and three with one of the parents) and
5 at school or day-care centre. In our study, 9 cases of per-
tussis were observed in four families: in three families 2
cases in each and in one family 3 cases. Before hospitali-
zation 28 (87.5%) patients had received antibiotic ther-
apy effective against B. pertussis (amoxicillin, ampicillin,
macrolide).
The rate of pertussis symptoms among fully immunized
children is shown in Table 2. The mean duration from the
onset of pertussis symptoms until hospitalization was
61.4 ± 68.3 days (range, 7 to 270 days; median 30). Most
of the children (22; 68.8%) had cough that lasted more
than three weeks. For 11 (34.4%) children who had had
two episodes (waves) of successive coughing, the mean
duration of cough was 127.3 ± 81.7 days (range, 40 to 270
days; median 90), and for 21 (65.6%) with one episode
26.9 ± 16.2 days (range, 7 to 70 days; median 30). The dif-
ference was statistically significant (Wilcoxon test, p <
0.0002).
The prevalence of other classical symptoms of pertussis
was following: paroxysmal cough 27 (84.4%), post-tus-
sive vomiting 10 (31.3%), 9 (28.1%) showed a typical
"whoop" and 1 (3.1%) apnea. Five (15.6%) children pre-
sented without classical symptoms of pertussis. The dura-
tion of their cough was 14 days and more, however, they
did not have any coughing paroxysms, whooping, post-
tussive vomiting or apnea.
Discussion
Lithuanian Centre of Infectious Disease Control and
Prophylaxis reported 162 cases of pertussis in 2001,
43.2% of them were vaccinated against pertussis. Almost
half of all patients (47.5%) with pertussis were aged 7–15
years. Our study analyzed the epidemiological data and
clinical presentation of 32 fully immunized children with
laboratory-confirmed pertussis hospitalized in the Centre
of Paediatrics, Vilnius University Children's Hospital
from May to December 2001. Detailed analysis of our
study data showed that fully vaccinated children got ill
with pertussis at the median of 11 years old (range, 4 to
15), after 9 years (range, 2.6 to 13) following four doses
vaccination with DTP vaccine. According to the data
reported in 1998 in Finland where pertussis vaccination
has been in practice for more than 40 years and a four-
dose schedule is completed before a child is 2 years old,
over the last decade the reported cases of pertussis
increased twice and most of the patients were schoolchil-
dren [4]. It is known that vaccine-induced immunity
wanes and after 5–10 years makes the vaccinated host vul-
nerable to infection [11,12]. Reported study from Poland
[13] revealed protective immunity against pertussis in
70% of six years old children, in 68% of seven and only in
45% of eight years old children. Thus, waning of immu-
nity, leads to a growing population of pertussis-suscepti-
ble older children, adolescents and an increasing
proportion of disease cases in these age groups. According
to the literature data vaccination with whole-cell vaccines
induces protective immunity lasting 6–8 years [11,14],
whereas protective immunity induced by vaccination with
acellular pertussis vaccine lasts 4–6 years and longer [15-
17]. Torvaldsen and McIntyre [18] showed that the fifth
Table 1: Characteristics of fully immunized children with 
pertussis
Characteristics n = 32 %
Age (years):
4–5 2 6.2
6–8 6 18.8
9–11 9 28.1
12–15 15 46.9
Gender:
Male 11 34.4
Female 21 65.6
Antibiotic treatment
before investigation 28 87.5
Table 2: Clinical symptoms of pertussis in fully immunized 
children
Symptoms n %
Cough 32 100
Duration of coughing (days):
7–14 7 21.9
15–21 3 9.3
22≥ 22 68.8
Paroxysmal cough 27 84.4
Whooping 9 28.1
Post-tussive vomiting 10 31.3
Apnea 1 3.1BMC Infectious Diseases 2005, 5:40 http://www.biomedcentral.com/1471-2334/5/40
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dose of pertussis vaccine given at 4–5 years of age reduced
the incidence of pertussis in older children.
Many studies have reported the importance of household
and school contacts for pertussis infection. The results of
the study performed in France during 1993 and 1994
showed that the source of pertussis was a close contact
with adult in 46% of identifiable cases, with sibling in
42% of cases and with other family members or friends in
11% of the cases [19]. More recently, in a household con-
tact study in the USA, 53% of people who were identified
as the primary source of pertussis infection were aged 13
years or older and 26% were aged 30 years or older [20].
Our study data showed that more than half of the patients
had been in contact with persons who had prolonged
cough: mostly in families and rarely at schools or day-care
centers.
Clinical presentation of pertussis in fully immunized chil-
dren become talking-point in the clinical practice. Various
factors such as patient's age, gender, antibiotic treatment
and especially vaccination status may influence clinical
presentation of pertussis. Vaccination significantly
changes the clinical presentation of pertussis [8-
10,21,22]. Prolonged cough is one of the classical symp-
toms of pertussis. Before investigation the median dura-
tion of cough in all our patients was one month. Tozzi et
al. [8] in a study of 788 laboratory confirmed cases of per-
tussis had demonstrated that the duration of cough in vac-
cinated children was about one month, while in
unvaccinated was two times longer. Two episodes of
cough and significantly prolonged cough (median 90
days) documented in our study may be accounted for co-
infection of B. pertussis with atypical pathogens. Hallander
et al. from Sweden [23] demonstrated that the duration of
cough increased when more than one agent was detected.
A median cough period was 51 days for B. pertussis and 60
days for co-infections with M. pneumoniae or  C.
pneumoniae.
Unvaccinated children more frequently presented the full
spectrum of classical pertussis symptoms than vaccinated
children. German study [9] has shown that 90.2% of
unvaccinated patients (mean age 4.3 years) had paroxys-
mal cough, 78.9% whooping and 53.3% post-tussive
vomiting. The frequency of paroxysmal cough in fully vac-
cinated children (median age 11 years) in our study was
similar (84.4%), but post-tussive vomiting and whooping
was more rare (accordingly 31.3% and 28.2%). Only one
11 years old patient had apnea. The results of our study
coincide to those reported from Canada [21]. Of the 103
immunized children (< 5 years of age), 68% developed
paroxysmal cough within the first week of their illness and
88% had persistent paroxysmal cough for more than three
weeks. Cough generally lasted 16–91 days (median 48). A
recent study conducted in Israel [10] has documented the
clinical manifestation of pertussis in previously immu-
nized children and young adults (median age 9 years).
21% of the patients had paroxysmal cough, 13% showed
post-tussive vomiting, 7% apnea and 6% had classic
whoop. The classical symptoms of our studied patients
therefore were more frequent compared with Israeli
patients. However, we should also take into account other
fully vaccinated children who had mild pertussis, but were
not referred to the hospital and were not recruited in our
study.
Some authors have reported that antibiotic treatment has
reduced the severity of pertussis and the duration of
cough, especially when they have been started at the
beginning of the disease [21]. In opposite, the other stud-
ies have demonstrated that antibiotic treatment does not
influence on the course of pertussis and is not effective
[24,25]. Tozzi et al. [8] has showed that children treated
with antibiotics had cough which lasted 6 to 11 days
longer and spasmodic cough 4 to 13 days longer than
untreated patients. Authors concluded that antibiotic
therapy may be a marker of severe disease. We had no pos-
sibility to evaluate the role of antibiotics on to the dura-
tion of the cough in our patients, because most of our
children had received antibiotics before examination.
The results of our study showed that prolonged cough in
fully vaccinated children are frequently associated with
paroxysmal cough and rarely with other symptoms such
as whooping, post-tussive vomiting, apnea. Only 15.6%
of the patients with a long duration of cough had no clas-
sical symptoms of pertussis. Thus, it is very difficult to sus-
pect pertussis in this group of children in the absence of
epidemiological data. Our data suggest that pertussis
should be considered in the differential diagnosis of pro-
longed cough in fully vaccinated children.
Conclusion
Pertussis is a common disease in Lithuania as well as in
many other countries with high vaccination coverage.
About half of children with pertussis in Lithuania in 2001
were aged 7 to14 years. Fully vaccinated children fell ill
with pertussis at the median of 11 years old, 9 years fol-
lowing DTP vaccination. More than half of the children
could catch pertussis at home, at school or at day-care
center. Clinical picture of pertussis in previously immu-
nized children is usually characterized by such classical
symptoms as prolonged and paroxysmal cough, rarely by
whopping and post-tussive vomiting, and very rarely by
apnea. This study provides useful information for the cli-
nicians about the epidemiology and clinical data of per-
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